Subgroup analysis of treatment effects for misclassified biomarkers with
  time-to-event data by Wan, Fang et al.
Subgroup analysis of treatment effects for misclassified biomarkers
with time-to-event data
Fang Wan, Andrew C. Titman, Thomas F. Jaki
Abstract
Analysing subgroups defined by biomarkers is of increasing importance in clinical research. In many
situations the biomarker is subject to misclassification error, meaning the subgroups are identified with
imperfect sensitivity and specificity. In these cases, it is improper to assume the Cox proportional
hazards model for the subgroup specific treatment effects for time-to-event data with respect to the true
subgroups, since the survival distributions with respect to the diagnosed subgroups will not adhere to the
proportional hazards assumption. This precludes the possibility of using simple adjustment procedures.
Instead, we present a method based on formally modelling the data as a mixture of Cox models using an
EM algorithm for estimation. An estimate of the overall population treatment effect is obtained through
the interpretation of the hazard ratio as a concordance odds. Profile likelihood is used to construct
individual and simultaneous confidence intervals of treatment effects. The resulting confidence intervals
are shown to have close to nominal coverage for moderately large sample sizes in simulations and the
method is illustrated on data from a renal-cell cancer trial.
1 Introduction
There is increasing acknowledgement of the existence of patient subgroups within clinical research. While
some treatments work well for all patients with the same disease, it has been shown that some treatments
are only effective for some subgroups of patients defined by a certain predictive biomarker [1, 2, 3, 4].
As a consequence, many clinical trials look to perform subgroup analysis to assess whether a treatment
is beneficial for those patients that are biomarker positive or biomarker negative and many trial designs
have been developed to account for these subgroups. Enrichment designs [5, 6] seek to identify the most
promising (sub)group of patients during the study while other designs optimize the cost-efficiency of the
trials via patients allocation with respect to their biomarker status (subgroup membership) [7, 8] or use a
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Figure 1: A biomarker stratified design
biomarker-strategy design [9]. All of these clinical trials assume 100% accuracy of the biomarker used in
defining subgroups. However, it is seldom possible to measure a biomarker with perfect diagnostic accuracy
meaning the observed subgroups will be subject to misclassification error. Without taking the sensitivity
and specificity of the biomarker into consideration, the resulting conclusion may be inaccurate [10, 11].
Existing methods that account for the sensitivity and specificity (see [10, 11]) consider normal and binary
endpoints only, while time-to-event data has not yet been considered.
In this paper, we propose a method to obtain point estimates and confidence intervals of the treatment
effects in biomarker stratified subgroups with time-to-event data for a biomarker by treatment interaction
design [12] (see Figure 1): Assume the total number of patients available to be enrolled into the trial is fixed
to be N . Patients are classified into two subgroups according to the observed status (positive or negative)
of a specific biomarker. In each of the two subgroups, patients are randomized into either the treatment
or control arm and are administered experimental treatment or placebo/active control accordingly. The
primary outcome, which is the survival time subject to right censoring, of all patients enrolled are recorded
for analysis.
The remainder of the article is organized as follows. In Section 2, the statistical model for misclassified
biomarker subgroups is defined. Section 3 gives estimation procedures for the model parameters, measures
of overall efficacy and construction of confidence intervals. Section 4 presents a simulation results to assess
the performance of the estimator and confidence intervals. The method is illustrated on a data example
relating to metastatic renal-cell cancer in Section 5. The article concludes with a discussion.
2 Statistical Model
Conditional on the true biomarker status, a proportional hazards model is assumed to hold. Specifically the
hazard at time t for patient i is taken as
hi(t;xi, zi) = h0(t) exp(β1xi + β2zi + γxizi) (2.1)
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where h0(t) is an unspecified baseline hazard function, xi and zi are binary indicators of treatment and true
biomarker status, respectively. Note that the biomarker status is 0 for the true negative subgroup and 1 for
the true positive subgroup. Further note that this model assumes that the biomarker status to be measured
without error in this model. Under this model, the hazard ratios associated with the treatment are exp(β1)
and exp(β1 + γ) for patients in the biomarker negative and positive group, respectively.
When the true biomarker status cannot be observed, a diagnostic test with imperfect sensitivity and speci-
ficity has to be used. Let vi ∈ {0, 1} be a binary indicator of whether the ith patient tests positive for the
biomarker. The marginal distribution of survival times among patients in each diagnosis group will then
be a mixture of Cox models corresponding to the models under true biomarker positive or negative status
and with the mixing proportions determined by the positive-predictive value (PPV) and negative-predictive
value (NPV) of the diagnostic test.
The PPV is given by
p+|⊕ :=
pi × λ1
pi × λ1 + (1− pi)(1− λ2) (2.2)
and NPV by
p−|	 :=
(1− pi)λ2
pi(1− λ1) + (1− pi)λ2 (2.3)
where the sensitivity, λ1, and the specificity, λ2 are assumed to be known and the prevalence of the biomarker,
pi, may either be considered known or will be estimated from the data.
The survivor function for patients observed to be positive and negative are then
S⊕(t;x) := S(t;x, v = 1) = p+|⊕S(t;x, z = 1) + (1− p+|⊕)S(t;x, z = 0) (2.4)
and
S	(t;x) := S(t;x, v = 0) = (1− p−|	)S(t;x, z = 1) + p−|	S(t;x, z = 0), (2.5)
respectively, where S(t;x, z) = exp{−H0(t) exp(β1x + β2z + γxz)} and H0(t) =
∫ t
0
h0(u)du is the baseline
cumulative hazard.
Note that unless there is either no treatment effect or the biomarker is observed without misclassification,
proportional hazards will not hold with respect to the treatment x, for either S⊕(t;x) or S	(t;x). Therefore
it is not possible to fit a Cox model to the observed data and perform some simple correction to adjust for
misclassification error. Instead, a formal likelihood-based estimation procedure is used.
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3 Estimation
Recently, Wu et al [13] proposed a Logistic-Cox mixture model in order to test for the existence of subgroups.
In their model a logistic regression model determines the effect of observable covariates on the probability of
membership of a mixture component. In each mixture component, times-to-event follow a Cox model with
different covariate effects.
The problem of correcting for misspecified biomarker status can be considered a special case of the framework
of Wu et al, where the mixing probabilities have a specific form that is fully specified given the prevalence,
pi, and the sensitivity and specificity.
In order to estimate the model proposed in Section 2, a semi-parametric maximum likelihood approach is
employed. A full likelihood for the data is constructed by making the standard assumption that the hazard
function h0(t) is piecewise constant between observed event times [14].
3.1 EM algorithm
Direct maximization of the likelihood is difficult or infeasible due to the large number of nuisance parameters
associated with the increments of the baseline hazard. Instead, taking a similar approach to various previous
authors [15, 16], an Expectation-Maximization (EM) algorithm is used. The true biomarker status is treated
as missing data, such that the ‘M’-step of the algorithm involves fitting a weighted Cox model, where each
patient has two sets of data corresponding to being truly biomarker positive or biomarker negative. The
weights correspond to the conditional probability of being truly biomarker positive (or negative) given the
current estimates of the parameters and the observed data (follow-up time, event indicator and diagnostic
test result).
Let ti, for i = 1, . . . , n, denote the follow up time for patient i and δi correspond to an event indicator, the
likelihood contribution of the ith observed data given positive and negative subgroup status is
L+i = [h0(ti) exp{(β1 + γ)xi + β2}]δi exp[−H0(ti) exp{(β1 + γ)xi + β2}]
and
L−i = [h0(ti) exp{β1xi}]δi exp[−H0(ti) exp{β1xi}],
where H0(t) denotes the cumulative baseline hazard.
The conditional weights are then given by
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wi := P (zi = 1|ti, δi,θ, xi, vi, H0(t))
=
(
p+|⊕L+i
p+|⊕L+i + (1− p+|⊕)L−i
)vi ( (1− p−|	)L+i
(1− p−|	)L+i + p−|	L−i
)1−vi
,
where θ = (β1, β2, γ). Note that the weights depend on both θ and H0. At each iteration, the M-step
first updates the estimates of θ and then updates hˆ0(t) and Hˆ0(t) using the Breslow’s estimator for the
baseline hazard from the weighted Cox model [14]. Let t(j) denote the jth ordered uncensored event time
and t(0) = 0. Then
hˆ0(t) = hj , for t(j−1) < t ≤ t(j),
where
hj =
{t(j) − t(j−1)}∑
l∈Rj
wl exp{(β1 + γ)xl + β2}+ (1− wl) exp{β1xl}
−1
and Rj = {i : ti ≥ t(j)} denotes the risk set of patients at time t(j).
These new estimates of θ and H0(t) are subsequently used to update the weights. When the prevalence
parameter pi is treated as unknown, it is also updated at each iteration, with the updated value of pi given
by n−1
∑
i wi. This involves also updating the values of p+|⊕ and p−|	 by plugging the new estimate of pi
into (2.2) and (2.3).
The marginal, or observed, likelihood for the data is given by
L(θ, Hˆ0(t), pi) =
∏
i
{P (ti, δi|xi, νi,θ, Hˆ0(t), pi)P (νi|pi)}.
If the prevalence of disease, pi, is known then the above likelihood can be expressed as
L(θ, Hˆ0(t)) =
∏
i
{p+|⊕L+i + (1− p+|⊕)L−i}vi{(1− p−|	)L+i + p−|	L−i}1−vi , (3.1)
which corresponds to the likelihood conditional on the observed diagnostic test results, vi. In the case where
pi is treated as unknown, we have
L(θ, Hˆ0(t), pi) =
∏
i
{pi × λ1L+i + (1− pi)× (1− λ2)L−i}vi×
{pi × (1− λ1)L+i + (1− pi)× λ2L−i}1−vi ,
(3.2)
with the difference between (3.1) and (3.2) arising because of the necessity to include terms relating to the
probabilities of observed values of vi in the latter case.
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3.2 Measures of overall efficacy
The use of hazard ratios for subgroup analysis of time-to-event data has been criticized due to the absence
of a constant hazard ratio in a mixture population and as a consequence, other methods based on median
survival and parametric modelling have been proposed to obtain ‘subgroup mixable’ estimates [18].
However, the hazard ratio between two groups in a proportional hazards model can also be expressed as the
concordance odds [19]. Specifically, if T0 and T1 are the survival times of two randomly chosen individuals
from groups 0 and 1 and the hazard ratio of group 1 compared to group 0 is ψ, then P (T0>T1)1−P (T0>T1) = ψ, or
equivalently
P (T0 > T1) =
ψ
1 + ψ
. (3.3)
The concordance odds has a clear clinical meaning and has the advantage that an estimate of the overall
concordance odds in a subgroup model can be found as a function of just the individual subgroup concordance
odds and the prevalence. It also has the advantages of not requiring either fully parametric estimation
procedures, which may be less robust, or fully non-parametric procedures which will be less efficient.
Let Ti, i = 0, 1 represent the survival time of a random subject in treatment arm i and Gi ∈ {0, 1}, i = 0, 1
represent the subgroup membership with P (Gi = 1) = pi, then
P (T0 > T1) = pi
2P (T0 > T1|G0 = G1 = 1) + (1− pi)2P (T0 > T1|G0 = G1 = 0)
+ pi(1− pi)P (T0 > T1|G0 = 0, G1 = 1) + pi(1− pi)P (T0 > T1|G0 = 1, G1 = 0),
hence
P (T0 > T1) = pi
2P (T01 > T11) + (1− pi)2P (T00 > T10) + pi(1− pi)P (T00 > T11) + pi(1− pi)P (T01 > T10)
where Tij is the survival time for a subject in treatment arm i and subgroup j. Each of the probabilities
on the right-hand side of the equation can be expressed in terms of the parameters β1, β2, γ of the model in
(2.1). Following (3.3), we have
P (T0 > T1) = pi
2expit(β1+γ)+(1−pi)2expit(β1)+pi(1−pi)expit(β1+β2+γ)+pi(1−pi)expit(β1−β2), (3.4)
where expit(x) = (1 + exp(−x))−1 is the inverse logit function. An estimate of the overall effect of a
treatment, expressed as concordance odds, is then given by Pˆ (T0>T1)
1−Pˆ (T0>T1) where Pˆ (T0 > T1) is obtained by
plugging the estimates of β1, β2, γ and pi into (3.4).
A disadvantage of the concordance odds as a measure of treatment efficacy is that there is no guarantee
that the overall efficacy measure lies in the interval between the two subgroup efficacy values. In fact, when
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γ = 0 but β2 6= 0 the overall concordance odds will be closer to 1 than exp(β1). Nevertheless it is virtually
impossible, in practice, for a contradictory result to occur, i.e. for there to be statistically significant benefits
for both subgroups but a non-significant overall effect. Such a situation could only occur if |βˆ2| is large and
SE(βˆ2) is large compared to both SE(βˆ1) and SE(βˆ1 + γˆ). Moreover it is impossible for the overall effect
to be of a different sign to the two subgroup effects.
3.3 Construction of confidence intervals
A convenient approach to constructing asymptotic confidence intervals for individual parameters is based
upon the profile likelihood ratio, which continues to have standard χ2 asymptotics even in the presence of a
potentially infinitely dimensional nuisance parameter [20]. For instance, to obtain a confidence interval for
the interaction, γ, we use the fact that
Λ(γˆ, γ0) = 2 log
L(θˆ, Hˆ0(t))
L(βˆ1, βˆ2, γ0, Hˆ0(t))
d−→ χ21
and hence take
{γ : Λ(γˆ, γ) ≤ χ21(1− α)}
as a (1 − α) × 100% confidence interval for γ. It is straightforward to find the maximum profile likelihood
estimates by using a modified EM algorithm where at each M-step the fixed parameter, e.g. γ, is treated as
a fixed offset term in the weighted Cox model.
For the subgroup analysis it is also desirable to construct a simultaneous confidence interval for the estimated
treatment effect in the biomarker positive and negative groups in order to control the familywise type I error
rate. In the parametrization used in (2.1) this corresponds to simultaneous confidence intervals for (β1 + γ)
and β1. In this case, the method proceeds by obtaining an estimate of the Hessian of the observed profile
likelihood with respect to (β1, γ). The method of Murphy and van der Vaart [21] is used to approximate
the profile likelihood information. This approach has also been used in other contexts where estimation
requires an EM algorithm [22]. The profile likelihood information is approximated by computing the profile
likelihood at values about (βˆ1, γˆ), perturbed by a suitably small value h to provide a ‘finite-differences’ type
approximation. Specifically,
Iβ1β1 ≈ −
lp(βˆ1 + 2h, γˆ)− 2lp(βˆ1 + h, γˆ) + lp(βˆ1, γˆ)
h2
,
Iβ1γ ≈ −
lp(βˆ1 + h, γˆ + h)− lp(βˆ1, γˆ + h)− lp(βˆ1 + h, γˆ) + lp(βˆ1, γˆ)
h2
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and
Iγγ ≈ − lp(βˆ1, γˆ + 2h)− 2lp(βˆ1, γˆ + h) + lp(βˆ1, γˆ)
h2
.
The value of h is primarily chosen to ensure that numerical stability in the converged values of the EM
algorithm do not affect the estimate. Theoretically, the value of h should decrease with increasing sample
size, but taking h = 0.01 worked adequately in the examples considered in this paper and the results were
not particularly sensitive to the choice of h.
By inverting the estimated information matrix I, an estimate of the variance-covariance matrix of (βˆ1+γˆ, βˆ1),
Σ =
( σ2+ ρσ+σ−
ρσ+σ− σ2−
)
,
is given by using the delta method
Σˆ =
(
1 1
1 0
)
I−1
(
1 1
1 0
)
.
Simultaneous confidence intervals are then constructed of the form
(βˆ1 + γˆ)± ξασ+
and
βˆ1 ± ξασ−
where ξα is the scaling factor chosen such that, for a bivariate normal random variable, X, with unit variances
and correlation ρ, P (|X1| ≤ ξα ∩ |X2| ≤ ξα) = 1 − α. This value can be found straightforwardly using the
qmvnorm function in the mvtnorm package in R [23, 24]. The procedure can be extended to provide simulta-
neous confidence intervals for the two subgroup effects and the overall log concordance odds by computing
the variance-covariance matrix of (βˆ1 + γˆ, βˆ1, βˆ
∗) using the delta method, where βˆ∗ = log
{
Pˆ (T0>T1)
1−Pˆ (T0>T1)
}
.
Obtaining an analytical form for the first derivatives can be cumbersome, but a numerical approximation
for the first derivatives can be used instead.
3.4 Missing biomarker status
In some trials, only a subset of patients may have had their biomarker status measured. If it can be assumed
that the missing diagnostic tests of biomarker status are missing at random, then the survivor function for
such patients, S(t;x), is given by:
S(t;x) = piS(t;x, z = 1) + (1− pi)S(t;x, z = 0).
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Such patients can easily be accommodated within the EM algorithm proposed in Section 3.1 by a simple
modification of the conditional weights for such patients. Specifically, the weight for a patient i with missing
diagnostic test is taken as
wi =
piL+i
piL+i + (1− pi)L−i .
Similarly, the marginal likelihood contribution of these patients, regardless of whether pi is taken as known
or to be estimated is simply given by
Li(θ, Hˆ0(t), pi) = piL+i + (1− pi)L−i.
4 Simulations
To investigate the finite sample properties of the proposed estimator data sets of varying sizes and levels
of biomarker subgroup diagnostic accuracy are simulated. The underlying survival hazards are assumed
to follow the model in (2.1), with a decreasing Weibull baseline hazard assumed such that h0(t) = 0.8 ×
0.10.8t−0.2.
Three scenarios are considered for the treatment effects. In the first, β1 = −0.5, β2 = 0.1 and γ = 0.3,
meaning the treatment is beneficial for both biomarker groups, but the effect is smaller for those who are
biomarker positive, corresponding to hazard ratios (HR) of 0.61 and 0.82. In the second, β1 = 0.1, β2 = 0.1
and γ = −0.7 corresponding to a stronger interaction effect where the treatment is beneficial for the biomarker
positive group but slightly harmful for the negative group (HRs of 0.55 and 1.11). Finally the third scenario,
β1 = 0, β2 = 0.1 and γ = 0, corresponds to a situation where the treatment has no effect in either biomarker
group.
Censoring is assumed to be independent and uniform distributed between 5 and 25, U(5, 25), which results in
an overall censoring rate of around 25%. The prevalence of a true positive biomarker status, pi, is taken to be
0.3 and treated as unknown in the estimation procedure. The effect of assuming rather than estimating the
prevalence is negligible in the simulation (where the prevalence given is accurate). However, if the prevalence
given is far from its true value, there should be an impact. The sensitivity and specificity of the diagnostic
test and the sample size per randomization group is varied across the simulation scenarios. The results
from 5000 replications of each scenario are presented in Tables 1, 2 and 3. The parameter estimates have
reasonably low levels of bias for all scenarios considered. As would be expected, the standard deviation of the
estimates increases as the diagnostic accuracy decreases. In the scenarios considered, since the prevalence is
lower than 0.5, imperfect specificity has a greater impact than imperfect sensitivity. The standard deviation
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of the estimate of γ is around 75% higher when the sensitivity and specificity are both 0.8 compared to the
case of perfect diagnostic accuracy. In the first scenario where the interaction effect is relatively modest, the
power to detect the interaction term is low in all scenarios, but substantially lower when there is diagnostic
error. For instance when the number in each randomization group is 500, the power reduces from 0.43, with
perfect diagnostic accuracy, to 0.17 with sensitivity and specificity both 0.8. A similar pattern is observed
in the second scenario, where the interaction effect is stronger. In the scenario with no interaction effect the
empirical Type I error of a test of interaction is close to 5% for all configurations, with a slight tendency to
be anti-conservative in the smaller sample size and when misclassification rates are higher.
Table 1: Bias and Standard Deviation (SD) of parameter estimates, empirical coverage of simultaneous
(Simult) nominal 95% confidence intervals of (β1, β1 + γ) and the empirical power of likelihood ratio test of
interaction term in the mild interaction scenario (β1, β2, γ) = (−0.5, 0.1, 0.3).
Bias ×102 SD Coverage Power
N (Sens, Spec) β1 β2 γ β1 β2 γ Simult γ 6= 0
100 (1,1) 0.0191 0.7232 -0.6650 0.2153 0.2634 0.3847 0.9472 0.1226
100 (1,0.8) -0.4598 0.9980 -2.0488 0.2416 0.3514 0.5154 0.9614 0.0902
100 (0.8,1) -0.6302 1.1681 -1.1618 0.2299 0.3017 0.4473 0.9512 0.1128
100 (0.9,0.9) -0.6628 1.1261 -1.2436 0.2383 0.3366 0.4960 0.9622 0.0912
100 (0.8,0.8) -0.4748 0.0643 -1.7780 0.2685 0.4767 0.6887 0.9596 0.0814
500 (1,1) 0.1274 0.2206 -0.2761 0.0965 0.1157 0.1670 0.9506 0.4286
500 (1,0.8) -0.1734 -0.1977 -0.0315 0.1077 0.1583 0.2280 0.9546 0.2490
500 (0.8,1) -0.3087 -0.1782 0.4508 0.1012 0.1333 0.1948 0.9522 0.3514
500 (0.9,0.9) -0.2142 -0.3322 0.1361 0.1052 0.1490 0.2172 0.9520 0.2834
500 (0.8,0.8) -0.1233 -0.4452 -0.3492 0.1218 0.2051 0.2949 0.9578 0.1678
The simultaneous confidence intervals for (β1, β1 + γ) have close to the nominal 95% level in all cases, with
a tendency to be slightly conservative.
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Table 2: Bias and Standard Deviation (SD) of parameter estimates, empirical coverage of simultaneous
(Simult) nominal 95% confidence intervals of (β1, β1 + γ) and the empirical power of likelihood ratio test of
interaction term in the strong interaction scenario (β1, β2, γ) = (0.1, 0.1,−0.7).
Bias ×102 SD Coverage Power
N (Sens, Spec) β1 β2 γ β1 β2 γ Simult γ 6= 0
100 (1,1) 0.1509 0.1085 -0.5872 0.2034 0.2581 0.3966 0.9468 0.4562
100 (1,0.8) -0.6065 -0.5878 1.0292 0.2210 0.3430 0.5144 0.9570 0.2968
100 (0.8,1) 0.0270 1.2441 -1.6333 0.2132 0.3004 0.4587 0.9516 0.3682
100 (0.9,0.9) -0.4779 -0.8028 -0.1945 0.2241 0.3650 0.5453 0.9578 0.2812
100 (0.8,0.8) -1.5560 0.6694 -1.3342 0.253 0.4714 0.8217 0.9502 0.2004
500 (1,1) 0.1167 0.1671 -0.5071 0.0900 0.1148 0.1705 0.9522 0.9878
500 (1,0.8) 0.1796 0.3993 -0.3036 0.0967 0.1480 0.2173 0.9566 0.9042
500 (0.8,1) 0.1194 0.1749 -0.1344 0.0926 0.1306 0.1975 0.9536 0.9452
500 (0.9,0.9) 0.1950 0.4669 -0.4286 0.0981 0.1563 0.2282 0.9556 0.8772
500 (0.8,0.8) -0.0108 0.6640 -0.0728 0.1126 0.2010 0.2959 0.9600 0.6752
5 Example: Pazonpanib for renal-cell cancer
As an illustrative example of the impact of accounting for misclassification of biomarkers in a survival study,
data from a Phase III trial of patients with metastatic renal-cell cancer are analyzed. The trial involved 343
patients, 225 of whom were randomized to treatment with Pazopanib, with the remaining 118 on placebo.
In addition, patients were classified by level of interleukin 6 (IL-6) into ‘low’ or ‘high’ groups. Interest lies
in determining whether Pazonpanib is an effective treatment for either or both groups of patient. In the
original analysis by Tran et al [25], it was assumed that the assay used to determine the level of IL-6 had
100% diagnostic sensitivity and specificity.
Here, the data are re-analysed considering the possibility of misclassification of IL-6 status. The individual
level data were reconstructed from the Kaplan-Meier estimates provided in Tran et al [25] using the method
of Guyot et al (2012) [26]. Following Liu et al [10], it is assumed that the assay has 95% sensitivity and 90%
specificity to distinguish high IL-6 from low.
Table 4 compares the results of an analysis assuming no misclassification with estimates using the proposed
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Table 3: Bias and Standard Deviation (SD) of parameter estimates, empirical coverage of simultaneous
(Simult) nominal 95% confidence intervals of (β1, β1 + γ) and the empirical Type I error of likelihood ratio
test of interaction term in the null scenario (β1, β2, γ) = (0, 0.1, 0).
Bias ×102 SD Coverage Type I err
N (Sens, Spec) β1 β2 γ β1 β2 γ Simult γ 6= 0
100 (1,1) 0.1389 0.0680 0.5389 0.2012 0.2629 0.3678 0.9508 0.0496
100 (1,0.8) -0.1232 0.5505 0.1944 0.222 0.3356 0.4798 0.9580 0.0588
100 (0.8,1) -0.0146 0.2379 1.2609 0.2155 0.3109 0.4396 0.9492 0.0620
100 (0.9,0.9) -0.0436 -0.8576 1.3769 0.2257 0.3644 0.5110 0.9590 0.0588
100 (0.8,0.8) -0.3072 0.6792 0.1749 0.2541 0.4698 0.7010 0.9608 0.0662
500 (1,1) 0.1800 0.4851 -0.4689 0.0899 0.1171 0.1657 0.9436 0.0572
500 (1,0.8) 0.2906 0.3950 -0.4087 0.0971 0.1480 0.2067 0.9528 0.0482
500 (0.8,1) 0.1894 0.1761 -0.0657 0.0928 0.1307 0.1848 0.9526 0.0508
500 (0.9,0.9) 0.3246 0.4625 -0.5343 0.0994 0.1563 0.2196 0.9556 0.0472
500 (0.8,0.8) 0.3481 0.6671 -0.630 0.1128 0.2011 0.2832 0.9622 0.0476
method. It is seen that the effect of adjusting for misclassification is to increase the estimated interaction
effect from -0.53 to -0.72, which also leads to the interaction being considered significant (p = 0.036).
Table 5 gives the estimates and simultaneous 95% confidence intervals for the concordance odds of Pazonpanib
for Low and High IL-6 patients. For both the original and misclassification analyses, the confidence interval
for Low IL-6 includes 1, implying no treatment effect, whilst the confidence interval for High IL-6 is entirely
below 1, indicating a treatment benefit.
6 Discussion
In this paper, we investigate subgroup analysis for time-to-event responses in biomarker stratified subgroups
with misclassificated biomarkers using a proportional hazards model. Point estimation and the construction
of (simultaneous) confidence intervals for the treatment effects in biomarker subgroups in the form of the
log-hazard ratio are provided. It is shown by simulation that the bias of the estimators and the coverage
probabilities of the simultaneous confidence intervals are acceptable for all considered simulation scenarios.
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Table 4: Comparison of estimates from original Cox model analysis assuming no biomarker misclassification
and model assuming 95% sensitivity and 90% specificity to detect High IL-6
Original analysis Misclassification corrected
Parameter Estimate 95% CI p-value Estimate 95% CI p-value
Pazonpanib (β1) -0.15 (-0.58, 0.27) 0.48 -0.12 (-0.57, 0.33) 0.58
High IL-6 (β2) 1.18 (0.73, 1.62) < 0.001 1.50 (0.96, 2.10) < 0.001
Interaction (γ) -0.53 (-1.08, 0.03) 0.06 -0.72 (-1.40, -0.05) 0.04
Prevalence (pi) - - - 0.47 (0.41, 0.53) -
Table 5: Simultaneous 95% confidence intervals for effect of Pazonpanib on overall survival for Low IL-6
patients, High IL-6 patients and all patients; CO=Concordance odds
Original analysis Misclassification corrected
Group CO 95% CI CO 95% CI
Low IL-6 0.86 (0.52, 1.41) 0.88 (0.52, 1.50)
High IL-6 0.51 (0.33, 0.77) 0.43 (0.25, 0.75)
All 0.70 (0.51 , 0.95) 0.67 (0.50 , 0.92)
It is also apparent from the simulation results that the power to detect a subgroup effect of treatment is
diminished in the presence of misclassification. Further work would be to develop sample size formulas
which would allow survival trials to be adequately powered to perform subgroup analysis in the presence of
biomarker misclassification.
The interpretation of a hazard ratio as the concordance odds allows an overall treatment effect estimate to
be computed in subgroup analyses of time-to-event data. While the focus of this paper has been cases with
misclassification of the biomarker status, the use of concordance odds can also be applied in the simpler case
where the biomarker status is perfectly observed.
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